

By: Parker

S.R. No. 14

R E S O L U T I O N

1 WHEREAS, Ehlers-Danlos Syndromes and Hypermobility Spectrum
2 Disorders Awareness Month took place in May 2023; and

3 WHEREAS, Ehlers-Danlos syndromes (EDS) include 13 heritable
4 connective tissue disorders that together affect an estimated 1 in
5 5,000 people; each disorder has its own set of symptoms, but all
6 types of EDS are characterized by joint hypermobility, skin
7 hyperextensibility, and tissue fragility; and

8 WHEREAS, Hypermobility spectrum disorders (HSD) are
9 connective tissue disorders that cause joint hypermobility,
10 instability, injury, and pain; in addition, other symptoms such as
11 fatigue, headaches, gastrointestinal problems, and autonomic
12 dysfunction are often a result of HSD; and

13 WHEREAS, There is currently no available cure for any type of
14 EDS or HSD, and treatments typically focus on addressing symptoms;
15 because the conditions can affect many different areas of the body,
16 patients often require multiple providers in different specialties
17 to manage their care; and

18 WHEREAS, Numerous patients impacted by EDS and HSD have
19 limited access to professionals who are knowledgeable about these
20 health issues; increased awareness about each condition is
21 necessary to help diagnose patients, improve symptom management,
22 and promote research initiatives; and

23 WHEREAS, More work remains to be done to ensure that all EDS
24 and HSD patients have access to quality health care, and the

S.R. No. 14

1 observance of Ehlers-Danlos Syndromes and Hypermobility Spectrum
2 Disorders Awareness Month unites people across Texas and around the
3 world in their commitment to that endeavor; now, therefore, be it

4 RESOLVED, That the Senate of the 88th Texas Legislature, 1st
5 Called Session, hereby recognize May 2023 as Ehlers-Danlos
6 Syndromes and Hypermobility Spectrum Disorders Awareness Month.